MEMPHASYS LIMITED. — Capital/Financing Update 2014

Jan 23, 2014

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 24] intentionally omitted <==

FOR IMMEDIATE RELEASE

Proposed Issue of Share Options

Sydney, Australia 24th January 2014 – NuSep Holdings Limited (ASX:NSP) wishes to advise the market that it has reached an agreement with two of its current loan providers for the issue of unlisted share options as per their current loan agreements. Please note, the current loan agreements are with related parties to NuSep Holdings Limited.

The terms of the proposed share options issuance are as follows:

1. The amount of unlisted share options to be issued is 3.00 million being 2.00 million to Ti Rakau Developments Ltd and/or nominee, a related party to current non-executive director Mr Andrew Goodall and 1.00 million to Ms Chang Seow Ying Alison and/or nominee, a related party to former nonexecutive director Mr Clifford Eu.

2. The unlisted share options will have an exercise price of 11.2 cents which is 150% of the five day Volume Weighted Average Price of NuSep Holdings trading days prior to 20th January 2014.

3. The unlisted share options expire in 24 months and specifically on 20th January 2016.

4. The issue of these unlisted share options is subject to shareholder approval at a future general meeting of NuSep Holdings Limited.

- END-

For more information please contact:

Contact: Prakash Patel Managing Director +61 2 8415 7300 prakash.patel@nusep.com

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques based on its PrIME[1] technology. The PrIME

1 PrIME stands for Pr eparative I solation by M embrane E lectrophoresis NuSep Holdings Ltd Postal Address Contact Details Email info@nusep.com 30 Richmond Rd P.O. Box 2202 Telephone +61 2 8415 7300 Web www.nusep.com Homebush NSW 2140 Homebush West NSW 2140 Facsimile +61 2 8415 7399 ABN 33 120 047 556

– 2 –

technology has produced a number of world firsts including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

• Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

• Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

• Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin .

For more information about NuSep please visit the company’s website www.NuSep.com

About PrIME Biologics Pte Ltd

PrIME Biologics is a Singapore based biotech company that has developed a disposable therapeutic plasma manufacturing process based on NuSep’s PrIME Technology. PrIME Biologics process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.

The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause ‘Mad Cow Disease’. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

The initial application for the PrIME process will be the Currently Unprocessable Plasma which represents approximately 50% of all the plasma collected in many Asian countries.